Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

The results for Lunsumio, also known as mosunetuzumab, and Polivy, also known as polatuzumab vedotin, came as part of a phase 3 study. Roche said it would now submit results to global health ...

Grupo Dia CEO Martín Tolcachir emphasised Dia's commitment to creating sustainable long-term value for its shareholders and ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral ...

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data ...

Adding polatuzumab vedotin (Polivy) to standard-of-care treatment significantly improved overall survival (OS) in patients ...

Polivy is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to an anti-cancer medicine. Polivy is used to treat ...